[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Biosimilar Insulin-Global Market Status and Trend Report 2013-2023

December 2017 | 158 pages | ID: BEB4ADF997BEN
MIReports Co., Limited

US$ 2,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

Biosimilar Insulin-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biosimilar Insulin industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Biosimilar Insulin 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Biosimilar Insulin worldwide, with company and product introduction, position in the Biosimilar Insulin market
Market status and development trend of Biosimilar Insulin by types and applications
Cost and profit status of Biosimilar Insulin, and marketing status
Market growth drivers and challenges

The report segments the global Biosimilar Insulin market as:

Global Biosimilar Insulin Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America
Europe
China
Japan
Rest APAC
Latin America

Global Biosimilar Insulin Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Rapid Acting Insulins
Short Acting Insulins
Intermediate Insulins
Long Lasting Insulins

Global Biosimilar Insulin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Clinic
Medical Center

Global Biosimilar Insulin Market: Manufacturers Segment Analysis (Company and Product introduction, Biosimilar Insulin Sales Volume, Revenue, Price and Gross Margin):

Pfizer
Biogenomics
Eli Lilly
Gan&Lee Pharmaceuticals
Geropharm
Julphar Gulf Pharmaceutical Industries
Paras Biopharmaceuticals
Samsung Bioepis
Sedico
Wockhardt
Teva Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

CHAPTER 1 OVERVIEW OF BIOSIMILAR INSULIN

1.1 Definition of Biosimilar Insulin in This Report
1.2 Commercial Types of Biosimilar Insulin
  1.2.1 Rapid Acting Insulins
  1.2.2 Short Acting Insulins
  1.2.3 Intermediate Insulins
  1.2.4 Long Lasting Insulins
1.3 Downstream Application of Biosimilar Insulin
  1.3.1 Hospital
  1.3.2 Clinic
  1.3.3 Medical Center
1.4 Development History of Biosimilar Insulin
1.5 Market Status and Trend of Biosimilar Insulin 2013-2023
  1.5.1 Global Biosimilar Insulin Market Status and Trend 2013-2023
  1.5.2 Regional Biosimilar Insulin Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Development of Biosimilar Insulin 2013-2017
2.2 Production Market of Biosimilar Insulin by Regions
  2.2.1 Production Volume of Biosimilar Insulin by Regions
  2.2.2 Production Value of Biosimilar Insulin by Regions
2.3 Demand Market of Biosimilar Insulin by Regions
2.4 Production and Demand Status of Biosimilar Insulin by Regions
  2.4.1 Production and Demand Status of Biosimilar Insulin by Regions 2013-2017
  2.4.2 Import and Export Status of Biosimilar Insulin by Regions 2013-2017

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

3.1 Production Volume of Biosimilar Insulin by Types
3.2 Production Value of Biosimilar Insulin by Types
3.3 Market Forecast of Biosimilar Insulin by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Biosimilar Insulin by Downstream Industry
4.2 Market Forecast of Biosimilar Insulin by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILAR INSULIN

5.1 Global Economy Situation and Trend Overview
5.2 Biosimilar Insulin Downstream Industry Situation and Trend Overview

CHAPTER 6 BIOSIMILAR INSULIN MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

6.1 Production Volume of Biosimilar Insulin by Major Manufacturers
6.2 Production Value of Biosimilar Insulin by Major Manufacturers
6.3 Basic Information of Biosimilar Insulin by Major Manufacturers
  6.3.1 Headquarters Location and Established Time of Biosimilar Insulin Major Manufacturer
  6.3.2 Employees and Revenue Level of Biosimilar Insulin Major Manufacturer
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 BIOSIMILAR INSULIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Pfizer
  7.1.1 Company profile
  7.1.2 Representative Biosimilar Insulin Product
  7.1.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Biogenomics
  7.2.1 Company profile
  7.2.2 Representative Biosimilar Insulin Product
  7.2.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Biogenomics
7.3 Eli Lilly
  7.3.1 Company profile
  7.3.2 Representative Biosimilar Insulin Product
  7.3.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Eli Lilly
7.4 Gan&Lee Pharmaceuticals
  7.4.1 Company profile
  7.4.2 Representative Biosimilar Insulin Product
  7.4.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Gan&Lee Pharmaceuticals
7.5 Geropharm
  7.5.1 Company profile
  7.5.2 Representative Biosimilar Insulin Product
  7.5.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Geropharm
7.6 Julphar Gulf Pharmaceutical Industries
  7.6.1 Company profile
  7.6.2 Representative Biosimilar Insulin Product
  7.6.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Julphar Gulf Pharmaceutical Industries
7.7 Paras Biopharmaceuticals
  7.7.1 Company profile
  7.7.2 Representative Biosimilar Insulin Product
  7.7.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Paras Biopharmaceuticals
7.8 Samsung Bioepis
  7.8.1 Company profile
  7.8.2 Representative Biosimilar Insulin Product
  7.8.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Samsung Bioepis
7.9 Sedico
  7.9.1 Company profile
  7.9.2 Representative Biosimilar Insulin Product
  7.9.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Sedico
7.10 Wockhardt
  7.10.1 Company profile
  7.10.2 Representative Biosimilar Insulin Product
  7.10.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Wockhardt
7.11 Teva Pharmaceuticals
  7.11.1 Company profile
  7.11.2 Representative Biosimilar Insulin Product
  7.11.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILAR INSULIN

8.1 Industry Chain of Biosimilar Insulin
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILAR INSULIN

9.1 Cost Structure Analysis of Biosimilar Insulin
9.2 Raw Materials Cost Analysis of Biosimilar Insulin
9.3 Labor Cost Analysis of Biosimilar Insulin
9.4 Manufacturing Expenses Analysis of Biosimilar Insulin

CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOSIMILAR INSULIN

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference


More Publications